The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Rare Gastrointestinal Diseases Treatment Market Increase Between 2026 And 2030?
The rare gastrointestinal diseases treatment market size has experienced significant growth in recent years. This market is anticipated to expand from $1.45 billion in 2025 to $1.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historic period’s growth drivers include increasing recognition of rare GI disorders, the expansion of specialty gastroenterology centers, the availability of immunosuppressive and anti-inflammatory drugs, rising clinical research activity, and improved diagnostic accuracy.
The market for rare gastrointestinal diseases treatment is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.91 billion by 2030, showing a compound annual growth rate (CAGR) of 5.6%. The expansion during the forecast period is attributable to the increasing development of orphan drugs, rising investments in rare disease research, the growing adoption of biologic therapies, the expansion of precision medicine approaches, and increasing patient access to advanced treatments. Key trends in this period include the increasing uptake of targeted biologic therapies, a rising focus on personalized treatment protocols, the growing use of advanced diagnostic devices, the expansion of enzyme replacement therapies, and enhanced integration of digital patient monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp
What Important Drivers Are Powering The Rare Gastrointestinal Diseases Treatment Market Growth?
The expansion of diagnostic testing is anticipated to boost the growth of the rare gastrointestinal diseases treatment market in the future. These medical procedures are utilized to identify, diagnose, or track illnesses, conditions, or infections in individuals. The growing need for such tests primarily stems from increased recognition of early disease identification, facilitating prompt interventions and enhanced patient results. Diagnostic testing is crucial for treating rare gastrointestinal diseases by allowing for precise and early detection of underlying ailments. It helps pinpoint specific disease mechanisms, enables tailored treatment strategies, and improves patient prognosis via early action. A noteworthy example is provided by the National Health Service, a UK-based government department, which reported that by December 2024, the volume of diagnostic tests conducted reached 2,544,809 in 2024, marking an increase from 2,312,030 in 2023. Consequently, the increase in diagnostic testing is fueling the expansion of the rare gastrointestinal diseases treatment market.
What Are The Core Segment Classifications In The Rare Gastrointestinal Diseases Treatment Market?
The rare gastrointestinal diseases treatment market covered in this report is segmented –
1) By Type: Drugs, Device
2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices
Which Trends Are Influencing The Expansion Of The Rare Gastrointestinal Diseases Treatment Market?
Leading enterprises within the rare gastrointestinal diseases treatment market are prioritizing the creation of novel therapies, such as fully human monoclonal antibodies, aimed at specific disease pathways to enhance patient results. These fully human monoclonal antibodies are antibodies crafted in laboratories exclusively from human proteins, designed to precisely identify and act on molecules responsible for illness, thereby blocking or modifying them with precision, boosting treatment efficacy and lessening adverse reactions. An illustration occurred in August 2023 when the US biotechnology firm, Regeneron Pharmaceuticals Inc., secured U.S. Food and Drug Administration (FDA) approval for its product Veopoz (pozelimab-bbfg), indicated for CHAPLE disease, which is a rare, severe, inherited gastrointestinal condition. As a fully human monoclonal antibody, Veopoz works by targeting complement factor C5, assisting in the regulation of the hyperactive complement system, which is implicated in protein loss and gastrointestinal harm in CHAPLE sufferers. This precise operational mechanism directly confronts the root cause of the ailment, thereby averting severe symptoms and potentially fatal complications.
Which Firms Are Competing In The Rare Gastrointestinal Diseases Treatment Market?
Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., Ellodi Pharmaceuticals Inc.
Access The Complete Rare Gastrointestinal Diseases Treatment Market Report:
Which Geographic Region Represents The Largest Rare Gastrointestinal Diseases Treatment Market Share?
North America was the largest region in the rare gastrointestinal diseases treatment market in 2025. The regions covered in the rare gastrointestinal diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rare Gastrointestinal Diseases Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp
Browse Through More Reports Similar to the Global Rare Gastrointestinal Diseases Treatment Market 2026, By The Business Research Company
Rare Diseases Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Gastrointestinal Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model